Technical Analysis for NEXI - NexImmune, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical NEXI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | 1.46% | |
| Oversold Stochastic | Weakness | 1.46% | |
| Crossed Above 20 DMA | Bullish | -4.88% | |
| Stochastic Reached Oversold | Weakness | -4.88% | |
| Oversold Stochastic | Weakness | -4.88% | |
| Fell Below 20 DMA | Bearish | -3.11% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 8 hours ago |
| 60 Minute Opening Range Breakout | about 10 hours ago |
| Up 1% | about 10 hours ago |
| Down 1% | about 12 hours ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.0 |
| 52 Week Low | 17.06 |
| Average Volume | 106,035 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 20.38 |
| 20-Day Moving Average | 19.34 |
| 10-Day Moving Average | 19.20 |
| Average True Range | 1.62 |
| ADX | 17.08 |
| +DI | 22.66 |
| -DI | 18.45 |
| Chandelier Exit (Long, 3 ATRs ) | 21.63 |
| Chandelier Exit (Short, 3 ATRs ) | 22.13 |
| Upper Bollinger Band | 21.99 |
| Lower Bollinger Band | 16.69 |
| Percent B (%b) | 0.38 |
| BandWidth | 27.41 |
| MACD Line | -0.37 |
| MACD Signal Line | -0.41 |
| MACD Histogram | 0.0431 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.93 | ||||
| Resistance 3 (R3) | 19.88 | 19.44 | 19.72 | ||
| Resistance 2 (R2) | 19.44 | 19.13 | 19.46 | 19.65 | |
| Resistance 1 (R1) | 19.07 | 18.94 | 19.26 | 19.12 | 19.59 |
| Pivot Point | 18.63 | 18.63 | 18.72 | 18.65 | 18.63 |
| Support 1 (S1) | 18.26 | 18.32 | 18.45 | 18.31 | 17.83 |
| Support 2 (S2) | 17.82 | 18.13 | 17.84 | 17.77 | |
| Support 3 (S3) | 17.45 | 17.82 | 17.70 | ||
| Support 4 (S4) | 17.50 |
